Pharma Pulse: Seven Stocks Surge into Spotlight on July 28

The pharmaceutical sector is buzzing with activity today as seven key players make headlines for strategic moves, regulatory wins, and legal developments. Here's a comprehensive breakdown of what’s driving investor attention.

Major Expansion Plans

- Laurus Labs has secured 531.77 acres in Andhra Pradesh’s IP Rambilli Phase-II to establish the Laurus 

Pharma Zone. The ₹5,630 crore investment will unfold over eight years, creating 6,350 jobs and boosting manufacturing capacity.

Regulatory Recalls and Approvals

- Sun Pharma is recalling 5,448 bottles of Lisdexamfetamine Dimesylate capsules in the US due to failed dissolution specifications.

- Lupin and Dr Reddy’s Laboratories are also initiating recalls over manufacturing issues and product mix-ups.

- Alembic Pharmaceuticals received final USFDA approval for Carbamazepine Extended-Release Tablets (100 mg, 200 mg, 400 mg), tapping into a $71 million market. This marks Alembic’s 225th ANDA approval.

Strategic Investments and Acquisitions

- Dr Reddy’s Laboratories has invested ₹565.4 crore in its Russian subsidiary, DRL Russia, acquiring a 45.19% equity stake to strengthen its global footprint.

- Genpharmasec acquired a 70% stake in Derren Healthcare for ₹34.15 crore, expanding its formulation manufacturing capabilities.

Legal Spotlight

- Zydus Lifesciences remains embroiled in a patent dispute with Roche over its breast cancer drug Sigrima. 

The Delhi High Court declined Roche’s request to access Zydus’ manufacturing process, citing procedural gaps under the Patents Act.

These developments position the pharma sector for dynamic movement in today’s trade, with investors closely watching regulatory outcomes and expansion strategies.

Source: The Hindu BusinessLine.